Last reviewed · How we verify
Previous denosumab
At a glance
| Generic name | Previous denosumab |
|---|---|
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer (PHASE4)
- Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases (PHASE2)
- Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.
- Outcome of Dental Implant Therapy in Patients Treated With Antiresorptive Medication
- Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer (EARLY_PHASE1)
- Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis (PHASE4)
- Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement (PHASE4)
- Denosumab for Prevention of Bone Complications After Bone Marrow Transplantation in Children (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Previous denosumab CI brief — competitive landscape report
- Previous denosumab updates RSS · CI watch RSS
- Amgen portfolio CI